TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for treatment-resistant PTSD —

Technology

A first-in-class approach to a body locked in alarm.

TraumaTone is a percutaneous bioelectronic implant designed to address the sympathetic root of PTSD. Restoring physiological baseline without systemic drug exposure.

The approach01 — 02

Decades of clinical evidence point to a specific sympathetic intervention as the most effective single lever for severe PTSD. Stimalia is the first to translate that science into a durable, programmable implant.

First-in-class

No approved implantable competitor exists in this space. Stimalia is creating the category.

Minimally invasive

One outpatient procedure. No daily medication. Designed for durable, programmable benefit.

Drug-free

No systemic pharmacology, no daily compliance burden, no medication interaction risk.

Clinical foundation02 — 02

Stimalia builds on decades of independent clinical evidence demonstrating 70–80% meaningful response rates when the relevant sympathetic mechanism is targeted directly. The biology is not the bet. Durable, scalable delivery is.

Stimalia

Bioelectronic medicine · Louvain La Neuve · est. 2025